Antal Tamás Zemplenyi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2479484/publications.pdf

Version: 2024-02-01

1040056 996975 19 263 9 15 citations g-index h-index papers 27 27 27 365 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Can cost–effectiveness principles be ignored in urgent times?. Journal of Comparative Effectiveness Research, 2022, 11, 7-9.	1.4	3
2	Re current acute pancreatitis prevention by the elimination of alcohol and ciga r ette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort study. BMJ Open, 2022, 12, e050821.	1.9	8
3	Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?. Applied Health Economics and Health Policy, 2022, 20, 291-303.	2.1	1
4	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. Health Economics (United Kingdom), 2022, , .	1.7	5
5	Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers. Journal of Comparative Effectiveness Research, 2022, 11, 905-913.	1.4	7
6	Cost-effectiveness analysis of invasive EEG monitoring in drug-resistant epilepsy. Epilepsy and Behavior, 2021, 114, 107488.	1.7	11
7	Early palliative care associated with lower costs for adults with advanced cancer: evidence from Hungary. European Journal of Cancer Care, 2021, 30, e13473.	1.5	2
8	Regulatory and HTA early dialogues in medical devices. Health Policy, 2021, 125, 1322-1329.	3.0	8
9	Survey of workflow and cost implications of decommissioning regarding the Falsified Medicines Directive in Hungarian hospital pharmacies. BMJ Open, 2021, 11, e047193.	1.9	1
10	Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. Pharmacoeconomics, 2020, 38, 1055-1070.	3.3	33
11	Implementation of palliative care consult Service in Hungary $\hat{a} \in \text{``integration barriers and facilitators.}$ BMC Palliative Care, 2020, 19, 41.	1.8	11
12	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. Frontiers in Public Health, 2020, 8, 612410.	2.7	9
13	Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. Croatian Medical Journal, 2020, 61, 252-259.	0.7	5
14	Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. BMC Health Services Research, 2019, 19, 131.	2.2	10
15	Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 105-113.	1.4	11
16	Direct healthcare cost of schizophrenia – European overview. European Psychiatry, 2018, 48, 79-92.	0.2	31
17	Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. European Journal of Cancer Care, 2018, 27, e12430.	1.5	47
18	Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. BMJ Open, 2018, 8, e021072.	1.9	21

#	Article	IF	CITATIONS
19	The effect of performance-volume limit on the DRG based acute care hospital financing in Hungary. Health Policy, 2014, 115, 152-156.	3.0	34